Impaired cube copy on the MOCA indicates worse performance in several cognitive domains in Parkinson´s disease
Objective: We aimed to identify if an impairment of the cube copy of the Montreal Cognitive assessment (MoCA) was associated with worse cognitive status in…Viewer responses to a virtual reality simulation of Parkinson’s disease psychosis
Objective: To examine the accuracy, effectiveness, and utility of a novel virtual reality (VR) simulation representing symptoms of Parkinson's disease psychosis (PDP). Background: Diagnosing PDP…GAITRite comparison between Parkinson’s disease stages
Objective: To compare gait performance across Parkinson's disease stages. Background: Parkinson's disease (PD) is characterized with changes in locomotion and posture, which are associated with…Gender and age-based differential item functioning (DIF) analysis of MDS-UPDRS
Objective: Test if DIF due to gender or age is present in MDS-UPDRS items. Background: Testing a rating scale for DIF is a core step…Home care program for patients with Parkinson’s disease – A Singapore experience
Objective: To review the disease profile of patients who were enrolled in the Home Care Program and evaluate the outcomes of the program. Background: With…Successful treatment of movement disorders after resection of midbrain cavernous malformations: Report of two cases
Objective: To evaluate the treatment of movement disorders which presented as a consequence of haemorrhage from midbrain cavernous malformations. Background: Few cases of movement disorders…Engrailed enhances dopamine synthesis in healthy dopaminergic neurons
Objective: The aim of the present study was to further elucidate the role of Engrailed in dopamine neurotransmission. Background: Engrailed1 and Engrailed2, collectively Engrailed, are…Computational assessment of calcium channel effects on subthalamic nucleus neuronal cells: Study of abnormal bursting patterns in Parkinson’s disease
Objective: Understanding the drug effects with respect to various ion channels on subthalamic nucleus (STN) cells is the key to safety pharmacology assessment. Here our…Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia
Objective: Nilotinib is FDA-approved for the treatment of chronic myeloid leukemia (CML) at 800mg oral dose twice daily. We examined the effects of lower doses…Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry
Objective: To evaluate the effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on motor fluctuations and dyskinesia in…
- « Previous Page
- 1
- …
- 353
- 354
- 355
- 356
- 357
- …
- 405
- Next Page »